NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹740.00.
| Holder | Stake |
|---|---|
| Life Insurance Corporation of India | 4.72% |
| Nishant Pradip Shah | 1.10% |
| Document | Date |
|---|---|
| Annual report FY2026 AARTI PHARMALABS LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY HEADLINE NUMBERS • Revenue Target: `400 Crores targeted revenue with 15-18% EBITDA CAGR | 2026-08-29 |
| Q1 FY27 earnings call AARTI PHARMALABS LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue (Standalone): INR 535 crores vs INR 375 crores YoY (+42%) • EBITDA: I | 2026-08-17 |
| Investor presentation · Q1 FY27 AARTI PHARMALABS LIMITED – Q1 FY27 SUMMARY HEADLINE NUMBERS • Q1 FY27 Revenue (Standalone): INR 5,346 Mn; +42.4% YoY (vs Q1 FY26: INR 3,753 Mn) • Q1 | 2026-08-10 |
| Quarterly results · Q1 FY27 AARTI PHARMALABS LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Q1 FY2027 Standalone Revenue from Operations (Net): Rs. 53,458.78 Lakhs • Q1 FY2027 S | 2026-08-07 |
| Q4 FY26 earnings call AARTI PHARMALABS LIMITED – Q4 FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY2026 Revenue: Rs.580 Crores (vs Rs.530 Crores in Q4 FY2025), up 9% Y-o | 2026-06-01 |
| Investor presentation · Q4 FY26 AARTI PHARMALABS LIMITED – INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Standalone Revenue: INR 17,976 million (1.5% YoY growth from INR 17,714 million | 2026-05-26 |
| Quarterly results · Q4 FY26 AARTI PHARMALABS LIMITED – FINANCIAL SUMMARY Document Date: May 25, 2026 --- HEADLINE NUMBERS • FY 2025-26 Revenue from Operations (Standalone): Rs | 2026-05-25 |
| Q3 FY26 earnings call AARTI PHARMALABS SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q3 FY26 Revenue: INR 425 crores vs INR 471 crores in Q3 FY25 (down 9.8%) • Q3 EBITD | 2026-02-16 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹2 / share ex-date Sep 15, 2026 | 2026-09-15 |
| Dividend | ₹1.50 / share ex-date Feb 16, 2026 | 2026-02-16 |
| Dividend | ₹2.50 / share ex-date Sep 15, 2025 | 2025-09-15 |
| Announcement | Date |
|---|---|
| Capacity addition announced for manufacturing operations Aarti Pharmalabs Limited has informed the Exchange regarding 'Capacity Addition'. | 2026-08-07 |
| Inaugurates new manufacturing block at Tarapur Unit 5 to expand capacity Aarti Pharmalabs Limited has inaugurated a new state-of-the-art manufacturing block at its Tarapur facility (Unit 5) in Maharashtra on June 30, 2026. This expansion is designed to increase t | 2026-06-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aarti Pharmalabs Limited — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.